



BrainsWay OCD Represents A Significant Transformation in OCD Treatment

Only platform TMS technology, enabling treatment of multiple indications, including MDD and OCD

- First non-invasive, novel FDA-cleared medical therapy for OCD in over a decade (FDA De Novo No. DEN170078)
- The depth and breadth of BrainsWay's H-coil technology enables targeting of multiple treatment areas

Current treatment methods are ineffective for a large segment of patients*

- Over 2 million adults are diagnosed with OCD each year. Approximately 50% of OCD patients are resistant to current first-line treatment methods, including CBT and SSRI medications

Many patients cannot tolerate medication side effects


- Patients often discontinue SSRIs due to debilitating side effects, such as weight gain, sexual dysfunction, suicidal thoughts, nausea, insomnia, and anxiety

*Ruscio AM, Stein DJ, Chiu WT, Kessler RC. "The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication." *Molecular Psychiatry*. 2008 Aug 26. McDougle CJ, Goodman WK, Leckman JF, Price LH. The psychopharmacology of obsessive-compulsive disorder implications for treatment and pathogenesis. *Psychiatr Clin North Am*. 1993;16:749-766



Large-scale, double-blinded multicenter RCT submitted to FDA demonstrates BrainsWay OCD treatment safe & effective

> 1 in 3 patients achieved over 30% reduction in Y-BOCS
 > 1 in 2 patients achieved over 20% reduction in Y-BOCS



- Response was achieved among patients who did not experience relief from SSRIs or psychotherapy
- Number Needed to Treat (NNT) of 3.7 after 6 weeks of treatment
- Low drop-out rate of 10.6%

- Patients remained on existing maintenance CBT and SSRI medications.
- Treatment consists of 5 sessions per week for 6 weeks, with a tailored provocation protocol during each session.

> 6.7 mean change in Y-BOCS from baseline achieved after 6 weeks
 > Improved CGI-I score maintained at week 10

